Old drug, new trick: can spironolactone silence HIV?
NCT ID NCT07415811
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This small, early study is testing whether spironolactone, a drug already approved for high blood pressure, can reduce the hidden HIV reservoir in people on effective HIV treatment. Researchers will give the drug to 12 adults (both with and without HIV) to see how it affects a key protein and how the body processes it. The goal is to gather initial safety and biological data to see if spironolactone could one day be part of an HIV cure strategy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Grupo de Pesquisa Clínica em Moléstias Infecciosas
São Paulo, São Paulo, 05401000, Brazil
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Peer support may lift the cloud of loneliness for older gay men with HIV
- Can peer mentors help gay men with HIV stay in care?
- HIV and hidden health risks: a major study probes the link
- Faith-Based therapy aims to heal trauma in young women
- Bringing HIV care to the community: a new test in zambia
- Could intense workouts reverse cognitive decline in older HIV patients?